PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.31%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-49.44%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
3.87%
Other expenses growth less than half of AGEN's 71.53%. David Dodd would verify if advantage is sustainable.
-37.34%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-37.34%
Both companies reducing total costs. Martin Whitman would check industry trends.
-62.14%
Interest expense reduction while AGEN shows 147.76% growth. Joel Greenblatt would examine advantage.
3.87%
D&A growth while AGEN reduces D&A. John Neff would investigate differences.
47.24%
EBITDA growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
37.34%
Operating income growth 50-75% of AGEN's 66.66%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
1271.24%
Other expenses growth above 1.5x AGEN's 71.53%. Michael Burry would check for concerning trends.
47.13%
Pre-tax income growth 50-75% of AGEN's 67.53%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
-62.14%
Both companies reducing tax expense. Martin Whitman would check patterns.
47.13%
Net income growth 50-75% of AGEN's 67.53%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
50.90%
EPS growth 50-75% of AGEN's 70.70%. Martin Whitman would scrutinize operations.
52.86%
Diluted EPS growth 50-75% of AGEN's 70.70%. Martin Whitman would scrutinize operations.
7.67%
Share count reduction below 50% of AGEN's 10.73%. Michael Burry would check for concerns.
12.32%
Diluted share reduction below 50% of AGEN's 10.73%. Michael Burry would check for concerns.